Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HLBBF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HLBBF and 80,000+ other tickers.
See exactly how HLBBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HLBBF and 80,000+ other tickers.
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, and other worldwide regions. Among its prominent offerings are Abilify Maintena and Rexulti/Rxulti, prescribed for schizophrenia; Brintellix/Trintellix and Rexulti/Rxulti for the management of depression; Vyepti for the prevention of migraine attacks…
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript
H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript
H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.